USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center.

USC-UCLA 药物性肝损伤 (DILI) 临床中心。

基本信息

批准号：
8627986
负责人：
ANDREW Abba STOLZ
金额：
$ 33.71万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-30 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8627986
关键词：
Acute Acute Liver Failure African American Alcoholic Liver Diseases Area Asia Asians Biological Markers Body Weight decreased California Censuses Clinical Clinical Research Clinical Treatment Clinical Trials Collection County County Hospitals Data Data Coordinating Center Databases Delaware Development Disease Doctor of Philosophy Enrollment Etiology Event Funding Future Genes Genetic Genetic Polymorphism Goals Hepatology Hispanics Immune Immune system Immunologist Incidence Individual Internet Knowledge Laboratories Latin America Los Angeles Medical center Medicine Native Americans Patient Recruitments Patients Pharmaceutical Preparations Plant Preparations Population Population Heterogeneity Proteomics Reaction Reporting Research Research Personnel Resources Rhode Island Role Scientific Advances and Accomplishments Serum Services Site Somatotype Specimen Surveys Talents Techniques United States United States National Institutes of Health Viral Vitamins Work acute drug induced liver toxicity base comparative disorder control drug mechanism drug quality experience follow-up genetic variant human disease insight instrument liver injury medical schools patient population programs public health relevance research clinical testing response treatment trial troglitazone usnic acid

项目摘要

DESCRIPTION (provided by applicant): The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) application in response to RFA-DK-13-003 "Continuation and Expansion of the Drug Induced Liver Injury Network (DILIN)" hopes to continue to participate with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our application will continue to combine the only two medical schools in Los Angeles County allowing us to continue to uniquely capture and enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.3 M residents of Los Angeles County (2011) are an unmatched resource composed of the most ethnically diverse population in the United States. Our application continues to utilize the expertise and talents from USC and UCLA medical centers. The enrollment of a large number of bona fide and ill patients with close follow up has demonstrated our CC's ability to capture DILIN cases in this diverse populations. The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1) Continue enrollment of high quality cases with collection of disease controls and acute cases for mechanistic studies; 2) Detailed analysis of cholestatic DILI due to HDS using genetic and serum analysis; 3) Immunological surveying of acute DILI cases compared with disease control to identify potential mechanism of liver injury; 4) Proteomic studies in acute cases of hepatocellular to identify mechanism of disease; and 5) Support of DILIN effort to develop assessment instruments and a treatment trial.

描述（由申请人提供）：USC-UCLA 药物性肝损伤临床中心 (CC) 响应 RFA-DK-13-003“药物性肝损伤网络 (DILIN) 的延续和扩展”的申请希望继续与其他 CC 一起参与推进 DILI 的科学知识和临床评估。我们的应用程序将继续结合洛杉矶县仅有的两所医学院，使我们能够继续以独特的方式捕获 DILI 病例并将其登记到由数据协调中心 (DCC) 监管的网络数据库中。洛杉矶县 (2011) 的 930 万居民是由美国种族最多元化的人口组成的无与伦比的资源。我们的应用程序继续利用南加州大学和加州大学洛杉矶分校医疗中心的专业知识和人才。大量真实患病患者的入组以及密切随访证明了我们的 CC 有能力在不同人群中捕获 DILIN 病例。继续开展 USC-UCLA DILI CC 的具体目标是： 1) 继续招募高质量病例，收集疾病控制病例和急性病例用于机制研究； 2) 使用遗传和血清分析详细分析 HDS 引起的胆汁淤积性 DILI； 3) 与疾病对照相比，对急性 DILI 病例进行免疫学调查，以确定肝损伤的潜在机制； 4) 急性肝细胞病例的蛋白质组学研究，以确定疾病机制； 5) 支持 DILIN 开发评估工具和治疗试验的努力。